Saltar ao contenido
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avanzado
  • Statin Cost-Effectiveness in t...
  • Citar
  • Text this
  • Enviar este rexistro por email
  • Imprimir
  • Exportar rexistro
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Permanent link
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Detalles Bibliográficos
Main Authors: Mihaylova, B, Briggs, A, Hlatky, M, Armitage, J, Parish, S, Gray, A, Collins, R, Study, HP
Formato: Journal article
Publicado: 2009
  • Existencias
  • Descripción
  • Títulos similares
  • Staff View
Descripción
Summary:

Títulos similares

  • Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
    por: Mihaylova, B, et al.
    Publicado: (2005)
  • Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
    por: Mihaylova, B, et al.
    Publicado: (2005)
  • Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
    por: Mihaylova, B, et al.
    Publicado: (2006)
  • Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
    por: Mihaylova, B, et al.
    Publicado: (2024)
  • The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
    por: Kent, S, et al.
    Publicado: (2016)

Opciones de procura

  • Historial de Procuras
  • Procura avanzada

Buscar Máis

  • Revisar o catálogo
  • Lista alfabética
  • Explore Channels
  • Reservas de curso
  • Novos exemplares

Necesita Axuda?

  • Consello de procura
  • Consulte a un Bibliotecario
  • Preguntas Frecuentes